Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents

Journal of Psychopharmacology

Volumn 22, Issue 5, 2008, Pages 511-521

  Marighetto, A ^a   Valerio, S ^a   Philippin, J N ^a   Bertaina Anglade, V ^b   Drieu La Rochelle, C ^b   Jaffard, R ^a   Morain, P ^c  

^a UMR 5287   (France)

^b Biotrial   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Aging; Mouse; Rat; Relational declarative memory; Spontaneous object recognition; Working memory

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; PIRIBEDIL;

AGE; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DECLARATIVE MEMORY; DRUG EFFECT; DRUG EFFICACY; MALE; MAZE TEST; MEMORY CONSOLIDATION; MEMORY DISORDER; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RADIAL MAZE TEST; RAT; RECOGNITION; SHORT TERM MEMORY; SPATIAL DISCRIMINATION; SPRAGUE DAWLEY RAT; TASK PERFORMANCE; WORKING MEMORY;

AGING; ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SUBCUTANEOUS; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; PIRIBEDIL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 43149105033     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107083836     Document Type: Article

References (53)

1. Bartholomeusz C.F., Box G., Van Rooy C., Nathan P.J. (2003) The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans. J Psychopharmacol 17: 9-15
2. Brown R.G., Marsden C.D. (1990) Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci 13: 21-29
3. Cagnotto A., Parotti L., Mennini T. (1996) In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur J Pharmacol 313: 63-67
4. Castro-Caldas A., Delwaide P., Jost W., Merello M., Williams A., Lamberti P., Aguilar M., Del Signore S., Cesaro P. (2006) The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 21: 500-509
5. Cohen N.J., Eichenbaum H., Deacedo B.S., Corkin S. (1985) Different memory systems underlying acquisition of procedural and declarative knowledge. Ann N Y Acad Sci 444: 54-71
6. Creese I. (1974) Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. Eur J Pharmacol 28: 55-58
7. DeBoer P., Abercrombie E.D., Heeringa M., Westerink B.H. (1993) Differential effect of systemic administration of bromocriptine and L-dopa on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats. Brain Res 608: 198-203
8. Downes J.J., Roberts A.C., Sahakian B.J., Evenden J.L., Morris R.G., Robbins T.W. (1989) Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 27: 1329-1343
9. Eichenbaum H. (2004) Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron 44: 109-120
10. Eichenbaum H., Otto T., Cohen N.J. (1992) The hippocampus - what does it do? Behav Neural Biol 57: 2-36
11. Ennaceur A., Delacour J. (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31: 47-59
12. Etchamendy N., Enderlin V., Marighetto A., Vouimba R.M., Pallet V., Jaffard R., Higueret P. (2001) Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling. J Neurosci 21: 6423-6429
13. Etchamendy N., Desmedt A., Cortes-Torrea C., Marighetto A., Jaffard R. (2003) Hippocampal lesions and discrimination performance of mice in the radial maze: sparing or impairment depending on the representational demands of the task. Hippocampus 13: 197-211
14. Gallagher M., Colombo P.J. (1995) Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 5: 161-168
15. Gobert A., Rivet J.M., Audinot V., Cistarelli L., Spedding M., Vian J., Peglion J.L., Millan M.J. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and 'silent' D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275: 899-913
16. Gobert A., Di Cara B., Cistarelli L., Millan M.J. (2003) Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther 305: 338-346
17. Goetz C.G., Poewe W., Rascol O., Sampaio C. (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20: 523-539
18. Hastak S.M. (2003) Treatment of memory impairment, vertigo and tinnitus in the elderly with piribedil in an Indian general practice setting. J Indian Med Assoc 101: 500-501
19. Higginson C.I., Wheelock V.L., Carroll K.E., Sigvardt K.A. (2005) Recognition memory in Parkinson's disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J Clin Exp Neuropsychol 27: 516-528
20. Jenner P. (1995) The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45: S6 - S12
21. Kline A.E., Massucci J.L., Marion D.W., Dixon C.E. (2002) Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. J Neurotrauma 19: 415-425
22. Kline A.E., Massucci J.L., Ma X., Zafonte R.D., Dixon C.E. (2004) Bromocriptine reduces lipid peroxidation and enhances spatial learning and hippocampal neuron survival in a rodent model of focal brain trauma. J Neurotrauma 21: 1712-1722
23. Lees A.J., Smith E. (1983) Cognitive deficits in the early stages of Parkinson's disease. Brain 106 (Pt 2). 257-270
24. Lewis S.J., Dove A., Robbins T.W., Barker R.A., Owen A.M. (2003) Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 23: 6351-6356
25. Lewis S.J., Slabosz A., Robbins T.W., Barker R.A., Owen A.M. (2005) Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 43: 823-832
26. Lieberman A., Kupersmith M., Neophytides A., Casson I., Durso R., Foo S.H., Khayali M., Bear G., Goldstein M. (1980) Long-term efficacy of bromocriptine in Parkinson disease. Neurology 30: 518-523
27. Marighetto A., Etchamendy N., Touzani K., Torrea C.C., Yee B.K., Rawlins J.N., Jaffard R. (1999) Knowing which and knowing what: a potential mouse model for age-related human declarative memory decline. Eur J Neurosci 11: 3312-3322
28. Marighetto A., Touzani K., Etchamendy N., Torrea C.C., De Nanteuil G., Guez D., Jaffard R., Morain P. (2000) Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor. Learn Mem 7: 159-169
29. Mehta M.A., Swainson R., Ogilvie A.D., Sahakian J., Robbins T.W. (2001) Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers. Psychopharmacology (Berl) 159: 10-20
30. Millan M.J., Peglion J.L., Vian J., Rivet J.M., Brocco M., Gobert A., Newman-Tancredi A., Dacquet C., Bervoets K., Girardon S. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275: 885-898
31. Millan M.J., Cussac D., Milligan G., Carr C., Audinot V., Gobert A., Lejeune F., Rivet J.M., Brocco M., Duqueyroix D., Nicolas J.P., Boutin J. A. Newman-Tancredi A (2001) Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 297: 876-887
32. Muslimovic D., Post B., Speelman J.D., Schmand B. (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65: 1239-1245
33. Nagaraja D., Jayashree S. (2001) Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 158: 1517-1519
34. Newman-Tancredi A., Cussac D., Audinot V., Nicolas J.P., De Ceuninck F., Boutin J.A., Millan M.J. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)- adrenoceptor. J Pharmacol Exp Ther 303: 805-814
35. Olson I., Page K., Moore K., Chaterjee A., Verfaelli M. (2006) Working memory for conjunctions relies on the medial temporal lobe. J Neurosci 26: 4596-4601
36. Owen A.M. (2004) Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 10: 525-537
37. Owen A.M., James M., Leigh P.N., Summers B.A., Marsden C.D., Quinn N.P., Lange K.W., Robbins T.W. (1992) Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115 (Pt 6). 1727-1751
38. Owen A.M., Iddon J.L., Hodges J.R., Summers B.A., Robbins T.W. (1997) Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia 35: 519-532
39. Parrao-Diaz T., Chana-Cuevas P., Juri-Claverias C., Kunstmann C., Tapia-Nunez J. (2005) Evaluation of cognitive impairment in a population of patients with Parkinson's disease by means of the mini mental Parkinson test. Rev Neurol 40: 339-344
40. Peretti C.S., Gierski F., Harrois S. (2004) Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology (Berl) 176: 175-181
41. Prickaerts J., Sik A., van der Staay F.J., de Vente J., Blokland A. (2005) Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation. Psychopharmacology (Berl) 177: 381-390
42. Puma C., Bizot J.C. (1998) Intraseptal infusions of a low dose of AP5, a NMDA receptor antagonist, improves memory in an object recognition task in rats. Neurosci Lett 248: 183-186
43. Rapp P.R., Stack E.C., Gallagher M. (1999) Morphometric studies of the aged hippocampus: I. Volumetric analysis in behaviorally characterized rats. J Comp Neurol 403: 459-470
44. Rascol O., Dubois B., Caldas A.C., Senn S., Del Signore S., Lees A. (2006) Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord 21: 2110-2115
45. Rosa R.M., Flores D.G., Appelt H.R., Braga A.L., Henriques J.A., Roesler R. (2003) Facilitation of long-term object recognition memory by pretraining administration of diphenyl diselenide in mice. Neurosci Lett 341: 217-220
46. Schuck S., Bentue-Ferrer D., Kleinermans D., Reymann J.M., Polard E., Gandon J.M., Allain H. (2002) Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 16: 57-65
47. Smith L.A., Tel B.C., Jackson M.J., Hansard M.J., Braceras R., Bonhomme C., Chezaubernard C., Del Signore S., Rose S., Jenner P. (2002) Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 17: 887-901
48. Staresina B.P., Davachi L. (2006) Differential encoding mechanisms for subsequent associative recognition and free recall. J Neurosci 26: 9162-9172
49. Touzani K., Marighetto A., Jaffard R. (2003) Fos imaging reveals ageing-related changes in hippocampal response to radial maze discrimination testing in mice. Eur J Neurosci 17: 628-640
50. Turle-Lorenzo N., Maurin B., Puma C., Chezaubernard C., Morain P., Baunez C., Nieoullon A., Amalric M. (2006) The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J Pharmacol Exp Ther 319: 914-923
51. Wallenstein G.V., Eichenbaum H., Hasselmo M.E. (1998) The hippocampus as an associator of discontiguous events. Trends Neurosci 21: 317-323
52. Ziegler M., Rondot P. (1999) Action of piribedil in Parkinson disease. Multicenter study. Presse Med 28: 1414-1418
53. Ziegler M., Castro-Caldas A., Del Signore S., Rascol O. (2003) Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord 18: 418-425